Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain
X Chi, X Liu, C Wang, X Zhang, X Li, J Hou… - Nature …, 2020 - nature.com
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spreads worldwide and
leads to an unprecedented medical burden and lives lost. Neutralizing antibodies provide …
leads to an unprecedented medical burden and lives lost. Neutralizing antibodies provide …
Structure-based neutralizing mechanisms for SARS-CoV-2 antibodies
Q Huang, X Han, J Yan - Emerging Microbes & Infections, 2022 - Taylor & Francis
The devastating economic and public health consequences caused by the COVID-19
pandemic have prompted outstanding efforts from the scientific community and …
pandemic have prompted outstanding efforts from the scientific community and …
Antibodies targeting a quaternary site on SARS-CoV-2 spike glycoprotein prevent viral receptor engagement by conformational locking
SARS-CoV-2 continues to evolve, with many variants evading clinically authorized
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
antibodies. To isolate monoclonal antibodies (mAbs) with broadly neutralizing capacities …
Antibodies that neutralize all current SARS-CoV-2 variants of concern by conformational locking
SUMMARY SARS-CoV-2 continues to evolve and evade most existing neutralizing
antibodies, including all clinically authorized antibodies. We have isolated and …
antibodies, including all clinically authorized antibodies. We have isolated and …
Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic
SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …
of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike …
Monoclonal antibody therapies against SARS-CoV-2
Monoclonal antibodies (mAbs) targeting the spike protein of SARS-CoV-2 have been widely
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
used in the ongoing COVID-19 pandemic. In this paper, we review the properties of mAbs …
Broadly neutralizing antibodies to SARS-CoV-2 provide novel insights into the neutralization of variants and other human coronaviruses
P Bajpai, V Singh, A Chandele… - Frontiers in Cellular and …, 2022 - frontiersin.org
Seven coronaviruses are known to cause infection/disease in humans. Of these, human
coronavirus (HCoV)-229E and HCoV-NL63 are alphacoronaviruses (α-CoVs), whereas …
coronavirus (HCoV)-229E and HCoV-NL63 are alphacoronaviruses (α-CoVs), whereas …
[HTML][HTML] Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition
Antibodies targeting the SARS-CoV-2 spike receptor-binding domain (RBD) are being
developed as therapeutics and are a major contributor to neutralizing antibody responses …
developed as therapeutics and are a major contributor to neutralizing antibody responses …
[HTML][HTML] Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies
Antibodies elicited in response to infection undergo somatic mutation in germinal centers
that can result in higher affinity for the cognate antigen. To determine the effects of somatic …
that can result in higher affinity for the cognate antigen. To determine the effects of somatic …
Potential for a plant-made SARS-CoV-2 neutralizing monoclonal antibody as a synergetic cocktail component
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a public health
crisis over the last two years. Monoclonal antibody (mAb)-based therapeutics against the …
crisis over the last two years. Monoclonal antibody (mAb)-based therapeutics against the …